This is a review of the evidence regarding the use of tramadol hydrochloride/paracetamol [Zaldiar®] which was approved for use in Australia by the Therapeutic Goods Administration (TGA) in 2012 for the indication of moderate pain in adults and adolescents aged upwards of 12 years.
Independent commentary by Associate Professor Stephen Gatt, Director, Administrative & Operational, Wales Anaesthesia, Prince of Wales Hospital, Senior Staff Specialist, Royal Hospital for Women, Associate Professor, Discipline of Anaesthesia, Critical Care & Emergency Medicine, University of New South Wales, President, Obstetric Anaesthesia Society of Asia & Oceania (OASAO).
Please login below to download this issue (PDF)